MITIGATE

Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours

 Coordinatore RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG 

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Mrs.
Nome: Melanie
Cognome: Stein
Email: send email
Telefono: +49 621 383 5575

 Nazionalità Coordinatore Germany [DE]
 Totale costo 5˙848˙215 €
 EC contributo 4˙494˙253 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

 Organization address address: SEMINARSTRASSE 2
city: HEIDELBERG
postcode: 69117

contact info
Titolo: Mrs.
Nome: Melanie
Cognome: Stein
Email: send email
Telefono: +49 621 383 5575

DE (HEIDELBERG) coordinator 1˙553˙768.00
2    EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG

 Organization address address: Neutorgasse 9/2
city: VIENNA
postcode: 1010

contact info
Titolo: Dr.
Nome: Pamela
Cognome: Zolda
Email: send email
Telefono: +43 15334064538
Fax: +43 15357041

AT (VIENNA) participant 464˙000.00
3    Advanced Accelerator Applications

 Organization address address: Rue Diesel 20
city: Saint Genis Pouilly
postcode: 1630

contact info
Titolo: Dr.
Nome: Jean Philippe
Cognome: Meunier
Email: send email
Telefono: +33 4 50993070
Fax: +33 4 50993071

FR (Saint Genis Pouilly) participant 449˙640.00
4    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Walter
Cognome: Krause
Email: send email
Telefono: +49 89 12052713
Fax: +49 89 12057534

DE (MUENCHEN) participant 405˙422.00
5    MEDIZINISCHE UNIVERSITAET INNSBRUCK

 Organization address address: Christoph-Probst Platz 1
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Prof.
Nome: Werner
Cognome: Jaschke
Email: send email
Telefono: +43 512 504 22761
Fax: +43 512 504 22758

AT (INNSBRUCK) participant 341˙400.00
6    RAPID BIOMEDIZINISCHE GERATE RAPID BIOMEDICAL GMBH

 Organization address address: KETTELERSTRASSE 3-11 PAV 2-4
city: RIMPAR
postcode: 97222

contact info
Titolo: Mr.
Nome: Kay
Cognome: Lipinski
Email: send email
Telefono: +49 9365 8826 32
Fax: +49 9365 8826 99

DE (RIMPAR) participant 329˙488.00
7    STEMCELL TECHNOLOGIES SARL

 Organization address address: MINIPAR POLYTEC RUE DES BERGES 40
city: GRENOBLE
postcode: 38000

contact info
Titolo: Mrs.
Nome: Marie-Claude
Cognome: Genevay
Email: send email
Telefono: +33 476047530
Fax: +33 476189963

FR (GRENOBLE) participant 312˙320.00
8    CAGE CHEMICALS SRL

 Organization address address: VIA BOVIO 6
city: NOVARA
postcode: 28100

contact info
Titolo: Dr.
Nome: Camilla
Cognome: Cavallotti
Email: send email
Telefono: 393212000000

IT (NOVARA) participant 307˙795.00
9    HOCHSCHULE MANNHEIM

 Organization address address: WINDECKSTRASSE 110
city: MANNHEIM
postcode: 68163

contact info
Titolo: Mr.
Nome: Winfried
Cognome: Hugo
Email: send email
Telefono: 496213000000

DE (MANNHEIM) participant 229˙500.00
10    UNIVERSITA DEGLI STUDI DI TORINO

 Organization address address: Via Giuseppe Verdi 8
city: TORINO
postcode: 10124

contact info
Titolo: Prof.
Nome: Giorgio
Cognome: Inghirami
Email: send email
Telefono: 390116000000
Fax: +39 01 16334623

IT (TORINO) participant 100˙920.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

disease    tumours    closed    molecular    techniques    models    invasive    therapeutic    pfs    imaging    patient    mutations    animal    loop    options    treatment    minimally    patients    months    smes    platform    probes    median   

 Obiettivo del progetto (Objective)

Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patient's type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.

Altri progetti dello stesso programma (FP7-HEALTH)

REFINEMENT (2011)

Financing systems’ effects on the Quality of Mental health care in Europe

Read More  

GO4HEALTH (2012)

"Formulating new Goals for global health, and proposing new Governance for global health that will allow the achievement of these goals"

Read More  

LUPAS (2009)

Luminescent polymers for in vivo imaging of amyloid signatures

Read More